Clinical Trial Update: H101 Combined With Camrelizumab for Recurrent Cervical Cancer [Phase 2]

View source ↗

Summary

A Phase 2 clinical trial evaluating H101 in combination with camrelizumab for recurrent cervical cancer is reported as ongoing with status unknown.

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cervical Cancer
• Uterine Cervical Neoplasms

Drugs mentioned

• Camrelizumab (camrelizumab)
• H101 (oncolytic adenovirus H101)

Snippet

Sponsor: Zhejiang Cancer Hospital | Conditions: Uterine Cervical Neoplasms, Oncolytic Virotherapy | Phase 2 | Status: UNKNOWN